News & Events

December 17, 2018

Alkahest Announces Positive Top-Line Data from Two Phase 2a Studies of AKST4290 in Individuals with Wet Age-Related Macular Degeneration

Both treatment naïve and treatment refractory individuals experienced improved visual acuity

SAN CARLOS, Calif., — Alkahest Inc., a clinical-stage biotechnology company focused on developing transformative therapies to treat age-related diseases, today announced top-line data from two... Continue Reading

December 4, 2018

Alkahest Doses First Subject in Phase 2 Clinical Trial of GRF6021 in Patients with Parkinson’s Disease and Cognitive Impairment

Grant funding by The Michael J. Fox Foundation will support Phase 2 trial

SAN CARLOS, Calif., — Alkahest Inc. ("Alkahest"), a clinical-stage biotechnology company focused on developing innovative therapies to treat age-related diseases, today announced dosing of the first subject in a Phase... Continue Reading

November 7, 2018

Alkahest Appoints Elizabeth Jeffords as Chief Commercial and Strategy Officer

SAN CARLOS, Calif., — Alkahest, Inc. ("Alkahest"), a clinical-stage biotechnology company focused on developing innovative therapies to treat age-related diseases, today announced the appointment of Elizabeth Jeffords as chief commercial and strategy officer.

"The expansion of our... Continue Reading

November 5, 2018

Alkahest to Present at the Society for Neuroscience Annual Meeting

Presentations highlight a novel multifactorial approach to treating neurodegenerative diseases

SAN CARLOS, Calif., — Alkahest, Inc. ("Alkahest"), a clinical-stage biotechnology company focused on developing innovative therapies to treat age-related diseases, today announced upcoming... Continue Reading

November 2, 2018

Alkahest Scientific Founder Tony Wyss-Coray Recognized as One of TIME Magazine’s 50 Most Influential People in Health Care

SAN CARLOS, Calif., — Alkahest Inc. ("Alkahest"), a clinical-stage biotechnology company focused on developing innovative therapies to treat age-related diseases, announced today that Tony Wyss-Coray Ph.D., Alkahest's co-founder and board member was named to TIME Health's list of... Continue Reading

October 29, 2018

Alkahest Presentation at Clinical Trials in Alzheimer’s Disease (CTAD) Conference October 26, 2018, Barcelona, Spain

Alkahest provided update on their novel multifactorial approach to the treatment of Alzheimer's Disease

SAN CARLOS, Calif., — Alkahest, Inc. ("Alkahest"), a clinical-stage biopharmaceutical company focused on developing innovative therapies to treat Alzheimer's Disease and other... Continue Reading

August 1, 2018

Alkahest, Inc. Announces Key Appointment

Bruce Morimoto joins Alkahest as Vice President, Drug Development Operations

SAN CARLOS, Calif.,  — Alkahest Inc. ("Alkahest"), a clinical-stage biotechnology company focused on developing new treatments for neurodegenerative diseases and other age-related conditions, announced today the... Continue Reading

July 23, 2018

Alkahest to Present at Alzheimer’s Association International Conference (AAIC) Annual Meeting July 22-26, 2018 Chicago, IL

Presentations highlight a novel multifactorial approach to the treatment of Alzheimer's Disease

SAN CARLOS, Calif.,  — Alkahest Inc. ("Alkahest"), a clinical-stage biotechnology company focused on developing innovative therapies to treat Alzheimer's Disease and other age-related diseases,... Continue Reading

June 18, 2018

Alkahest, Inc. Announces Key Appointment

Michael Byrnes joins Alkahest as Chief Financial Officer

SAN CARLOS, Calif.,  — Alkahest Inc. ("Alkahest"), a clinical-stage biotechnology company focused on developing new treatments for neurodegenerative diseases and other age-related conditions, announced today the appointment of... Continue Reading

May 21, 2018

Alkahest Receives Grant from Michael J. Fox Foundation; Funding Will Support Preclinical Evaluation of ALK4290 for Parkinson’s Disease

SAN CARLOS, Calif., — Alkahest, Inc. ("Alkahest"), a clinical-stage biotechnology company focused on developing innovative therapies to treat age-related diseases, today announced that it has been awarded a grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) entitled... Continue Reading